6533b835fe1ef96bd12a015a

RESEARCH PRODUCT

Effects of Chitosan on Plasma Lipids and Lipoproteins

Giuseppe MontaltoRosaria Vincenza GiglioDragana NikolicClaudia CampanellaRizzo ManfrediMassimo CocchiAngelo Maria PattiNiki Katsiki

subject

Malechitosan; lipids; lipoproteins; therapymedicine.medical_specialtyFuture studiesPilot ProjectsFixed doseBody Mass IndexChitosanchemistry.chemical_compoundlipidInternal medicinePlasma lipidsmedicineHumansProspective StudiesPolyacrylamide gel electrophoresisTriglyceridesHypertriglyceridemiaLdl cholesteroltherapybusiness.industryAnticholesteremic AgentslipoproteinMiddle AgedLipoproteins LDLCholesterolEndocrinologychemistryConcomitantFemalelipids (amino acids peptides and proteins)Waist CircumferencechitosanLipoproteins HDLCardiology and Cardiovascular MedicinebusinessLipoprotein

description

Chitosan can favorably modulate plasma lipids, but the available data are not conclusive. We evaluated the effect of chitosan on plasma lipids and lipoproteins in 28 patients with plasma triglyceride levels >150 mg/dL (mean age: 63 ± 12 years), not taking other lipid-lowering agents. All patients received a chitosan derived from fungal mycelium (Xantonet, Bromatech, Italy) at a fixed dose of 125 mg/d in addition to their current medications for 4 months. Polyacrylamide gel electrophoresis was used to measure low-density lipoprotein (LDL) subclasses. After treatment, total cholesterol reduced by 8%, LDL cholesterol by 2%, and triglycerides by 19%, with a concomitant 14% increase in high-density lipoprotein cholesterol. We also found a beneficial effect of chitosan on LDL subclasses, with a significant increase in LDL-2 particles (from 37 ± 8% to 47 ± 8%, P = .0001) and a decrease (although not significant) in atherogenic small, dense LDL. Whether these findings may affect cardiovascular risk remains to be established in future studies.

yearjournalcountryeditionlanguage
2014-01-01Angiology
https://doi.org/10.1177/0003319713493126